Medicine and Dentistry
Gastrointestinal Stromal Tumor
100%
Patient
97%
Imatinib
34%
Neoplasm
33%
Therapeutic Procedure
27%
Surgery
19%
Survival
18%
Biopsy
16%
Recurrent Disease
15%
Floxuridine
15%
Gastrointestinal Stromal Tumor
14%
Chemotherapy
13%
Young Adult
12%
Exon
12%
Inpatient
11%
Recurrence Free Survival
10%
Proportional Hazards Model
10%
Overall Survival
10%
Male
10%
Sunitinib
9%
Colorectal Liver Metastasis
9%
Sex Difference
8%
Retrospective Study
8%
Hepatic Arterial Infusion
8%
PET-CT
7%
Rupture
7%
Diagnosis
6%
Pump
6%
Female
6%
Sex
6%
Older Adult
6%
Small Intestine
6%
Stomach
6%
Hazard Ratio
5%
Mutant
5%
Disease Specific Survival
5%
Pharmacology, Toxicology and Pharmaceutical Science
Gastrointestinal Stromal Tumor
65%
Imatinib
37%
Survival
15%
Neoplasm
15%
Floxuridine
15%
Recurrent Disease
12%
Sunitinib
11%
Recurrence Free Survival
10%
Overall Survival
10%
Colorectal Liver Metastasis
9%
Infusion Pump
8%
Rupture
7%
Protein Tyrosine Kinase Inhibitor
6%
Side Effect
5%
Disease Specific Survival
5%
Biochemistry, Genetics and Molecular Biology
Mutation
14%
Imatinib
13%
Stomach
11%
Sunitinib
9%
Sex Difference
8%
Dose
7%
Sex
6%
PDGFRA
5%
Mutant
5%
Survival
5%
Disease Specific Survival
5%